Avocet Bio

Executive Summary

Avocet Bio is a Munich-based biotechnology company founded in 2021, focusing on programmable platform technologies to target any RNA-based virus. The company aims to develop broad-spectrum antiviral solutions, addressing the urgent need for pandemic preparedness against current and future viral threats. By leveraging a disruptive platform approach, Avocet Bio seeks to overcome the limitations of traditional antivirals, which often target specific viruses and quickly become obsolete due to viral mutations. The platform's ability to be rapidly reprogrammed against emerging RNA viruses positions it as a potential game-changer in the field of antiviral therapeutics. While still in early stages with no disclosed funding or valuation, Avocet Bio's concept aligns with growing global interest in broad-spectrum antivirals, particularly after the COVID-19 pandemic. The company's success will depend on demonstrating preclinical proof-of-concept, securing funding, and forming strategic partnerships. Given the early stage, the conviction score is moderate, reflecting the high risk but significant potential of the platform technology.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q4 2026Preclinical Proof-of-Concept Data for Lead Program50% success
• Q3 2026Collaboration or Licensing Agreement with Academic Institution40% success